Skip to main content
Top
Published in: Rheumatology International 10/2018

01-10-2018 | Cohort Studies

A retrospective study comparing the phenotype and outcomes of patients with polyarteritis nodosa between UK and Turkish cohorts

Authors: Omer Karadag, Abdulsamet Erden, Yelda Bilginer, Seerapani Gopaluni, Alper Sari, Berkan Armagan, Ihsan Ertenli, Seza Ozen, David Jayne

Published in: Rheumatology International | Issue 10/2018

Login to get access

Abstract

There is a need for better definition of polyarteritis nodosa (PAN) subphenotypes and the influence of ethnicity and geography. This study is aimed to study the demographic and clinical features of PAN cohorts from the UK and Turkey (TR) and to compare and contrast disease characteristics. A retrospective survey of databases from two vasculitis centres between 1990 and 2016 for PAN patients fulfilling the EMEA Vasculitis Classification algorithm. All paediatric-onset adult patients met the Ankara 2008 (EULAR/PReS endorsed) criteria for childhood PAN. Those with typical angiographic and/or histopathologic findings consistent with PAN were included. 93 (M/F: 51/42) patients (UK: 47, TR: 46) were included. Three were HBV-related, 20 (21.5%) had paediatric onset and 16 (16.5%), cutaneous PAN. TR patients had younger age of disease onset 44 (28.5–59.0) vs. 24.5 (11.8–40.5), p = 0.002. Twelve (26%) of TR patients had monogenic disease (Familial Mediterranean Fever association (n = 7), deficiency of adenosine deaminase 2, DADA2, (n = 5). No difference was found in phenotype between paediatric and adult onset patients except for frequency of cutaneous lesions (p = 0.002). During a median 67.5 (32–126) months follow-up, 13 patients died (12.7% in UK vs. 15.2% in Turkish cohorts). No difference was found between two cohorts in relation to relapse rate, death and vasculitis damage index. This study defined a diagnosis of PAN according to the EMEA algorithm. The TR group had a younger age of disease onset and more cases of monogenic disease; however, disease extent, relapse rate, damage index and death rates were similar between groups.
Literature
1.
go back to reference Kussmaul A, Maier R (1866) Ueber eine bisher nicht beschriebene eigenthu ̈mliche Arterienerkrankung (Periarteritis nodosa), die mit Morbus Brightii und rapid fortschreitender allgemeiner Muskel- l ̈ahmung einhergeht. Dtsch Arch Klin Med 1:484–518 Kussmaul A, Maier R (1866) Ueber eine bisher nicht beschriebene eigenthu ̈mliche Arterienerkrankung (Periarteritis nodosa), die mit Morbus Brightii und rapid fortschreitender allgemeiner Muskel- l ̈ahmung einhergeht. Dtsch Arch Klin Med 1:484–518
2.
go back to reference Pagnoux C, Seror R, Henegar C, Mahr A, Cohen P, Le Guern V et al (2010) Clinical features and outcomes in 348 patients with polyarteritis nodosa: a systematic retrospective study of patients diagnosed between 1963 and 2005 and entered into the French Vasculitis Study Group Database. Arthritis Rheum 62(2):616–626CrossRefPubMed Pagnoux C, Seror R, Henegar C, Mahr A, Cohen P, Le Guern V et al (2010) Clinical features and outcomes in 348 patients with polyarteritis nodosa: a systematic retrospective study of patients diagnosed between 1963 and 2005 and entered into the French Vasculitis Study Group Database. Arthritis Rheum 62(2):616–626CrossRefPubMed
3.
go back to reference Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F et al (2012) Revised international Chapel Hill consensus conference nomenclature of vasculitides. Arthritis Rheum 65:1–11CrossRef Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F et al (2012) Revised international Chapel Hill consensus conference nomenclature of vasculitides. Arthritis Rheum 65:1–11CrossRef
4.
go back to reference Tunca M, Akar S, Onen F, Ozdogan H, Kasapcopur O, Yalcinkaya F et al (2005) Familial Mediterranean Fever (FMF) in Turkey: results of a nationwide multicenter study. Medicine (Baltimore) 84:1–11CrossRef Tunca M, Akar S, Onen F, Ozdogan H, Kasapcopur O, Yalcinkaya F et al (2005) Familial Mediterranean Fever (FMF) in Turkey: results of a nationwide multicenter study. Medicine (Baltimore) 84:1–11CrossRef
5.
go back to reference Kermani TA, Ham EK, Camilleri MJ, Warrington KJ (2012) Polyarteritis nodosa-like vasculitis in association with minocycline use: a single-center case series. Semin Arthritis Rheum 42:213–221CrossRefPubMed Kermani TA, Ham EK, Camilleri MJ, Warrington KJ (2012) Polyarteritis nodosa-like vasculitis in association with minocycline use: a single-center case series. Semin Arthritis Rheum 42:213–221CrossRefPubMed
6.
go back to reference Navon Elkan P, Pierce SB, Segel R, Walsh T, Barash J, Pedeh S, Zlotogorski A et al (2014) Mutant adenosine deaminase 2 in a polyarteritis nodosa vasculopathy. N Engl J Med 370:921–931CrossRefPubMed Navon Elkan P, Pierce SB, Segel R, Walsh T, Barash J, Pedeh S, Zlotogorski A et al (2014) Mutant adenosine deaminase 2 in a polyarteritis nodosa vasculopathy. N Engl J Med 370:921–931CrossRefPubMed
7.
go back to reference de Menthon M, Mahr A (2011) Treating polyarteritis nodosa: current state of the art. Clin Exp Rheumatol 29(1 Suppl 64):S110–S116PubMed de Menthon M, Mahr A (2011) Treating polyarteritis nodosa: current state of the art. Clin Exp Rheumatol 29(1 Suppl 64):S110–S116PubMed
8.
go back to reference Erden A, Batu ED, Bilgin E, Armagan B, Karadag O, Ozen S et al (2016) Comparing the characteristics of adult and pediatric patients with polyarteritis nodosa. Ann Rheum Dis 75:799 Erden A, Batu ED, Bilgin E, Armagan B, Karadag O, Ozen S et al (2016) Comparing the characteristics of adult and pediatric patients with polyarteritis nodosa. Ann Rheum Dis 75:799
10.
go back to reference Craven A, Robson J, Ponte C, Grayson PC, Suppiah RS, Watts RA et al (2013) ACR/EULAR-endorsed study to develop diagnostic and classification criteria for vasculitis (DCVAS). Clin Exp Nephrol 17:619–621CrossRefPubMed Craven A, Robson J, Ponte C, Grayson PC, Suppiah RS, Watts RA et al (2013) ACR/EULAR-endorsed study to develop diagnostic and classification criteria for vasculitis (DCVAS). Clin Exp Nephrol 17:619–621CrossRefPubMed
11.
go back to reference Watts R, Lane S, Hanslik T, Hauser T, Hellmich B, Koldinsnes W et al (2007) Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis 66:222–227CrossRefPubMed Watts R, Lane S, Hanslik T, Hauser T, Hellmich B, Koldinsnes W et al (2007) Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis 66:222–227CrossRefPubMed
12.
go back to reference De Groot K, Gross WL, Herlyn K, Reinhold-Keller E (2001) Development and validation of a disease extent index for Wegener’s granulomatosis. Clin Nephrol 55:31–38PubMed De Groot K, Gross WL, Herlyn K, Reinhold-Keller E (2001) Development and validation of a disease extent index for Wegener’s granulomatosis. Clin Nephrol 55:31–38PubMed
13.
go back to reference Guillevin L, Lhote F, Gayraud M, Cohen P, Jarrousse B, Lortholary O et al (1996) Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. Medicine (Baltimore) 75:17–28CrossRef Guillevin L, Lhote F, Gayraud M, Cohen P, Jarrousse B, Lortholary O et al (1996) Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. Medicine (Baltimore) 75:17–28CrossRef
14.
go back to reference Exley AR, Bacon PA, Luqmani RA, Kitas GD, Gordon C, Savage CO et al (1997) Development and initial validation of the vasculitis damage index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum 40:371–380CrossRefPubMed Exley AR, Bacon PA, Luqmani RA, Kitas GD, Gordon C, Savage CO et al (1997) Development and initial validation of the vasculitis damage index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum 40:371–380CrossRefPubMed
15.
go back to reference Alibaz-Oner F, Koster MJ, Crowson CS, Makol A, Yterberg SR, Salvarani C et al (2017) The clinical spectrum of medium-sized vessel vasculitis. Arthritis Care Res (Hoboken) 69:884–891CrossRef Alibaz-Oner F, Koster MJ, Crowson CS, Makol A, Yterberg SR, Salvarani C et al (2017) The clinical spectrum of medium-sized vessel vasculitis. Arthritis Care Res (Hoboken) 69:884–891CrossRef
16.
go back to reference Ozen S (2017) The changing face of polyarteritis nodosa and necrotizing vasculitis. Nat Rev Rheumatol 13:381–386CrossRefPubMed Ozen S (2017) The changing face of polyarteritis nodosa and necrotizing vasculitis. Nat Rev Rheumatol 13:381–386CrossRefPubMed
17.
go back to reference Mahr A, Guillevin L, Poissonnet M, Aymé S (2004) Prevalences of polyarteritis nodosa, microscopic polyangiitis, Wegener’s granulomatosis, and Churg-Strauss syndrome in a French urban multiethnic population in 2000: a capture–recapture estimate. Arthritis Rheum 51:92–99CrossRefPubMed Mahr A, Guillevin L, Poissonnet M, Aymé S (2004) Prevalences of polyarteritis nodosa, microscopic polyangiitis, Wegener’s granulomatosis, and Churg-Strauss syndrome in a French urban multiethnic population in 2000: a capture–recapture estimate. Arthritis Rheum 51:92–99CrossRefPubMed
18.
go back to reference Guillevin L, Mahr A, Callard P, Godmer P, Pagnoux C, Leray E et al, French Vasculitis Study Group (2005) Hepatitis B virus-associated polyarteritis nodosa: clinical characteristics, outcome, and impact of treatment in 115 patients. Medicine (Baltimore) 84:313–322CrossRef Guillevin L, Mahr A, Callard P, Godmer P, Pagnoux C, Leray E et al, French Vasculitis Study Group (2005) Hepatitis B virus-associated polyarteritis nodosa: clinical characteristics, outcome, and impact of treatment in 115 patients. Medicine (Baltimore) 84:313–322CrossRef
19.
go back to reference Gayraud M, Guillevin L, le Toumelin P, Cohen P, Lhote F, Casassus P et al, French Vasculitis Study Group (2001) Long-term followup of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients. Arthritis Rheum 44:666–675CrossRefPubMed Gayraud M, Guillevin L, le Toumelin P, Cohen P, Lhote F, Casassus P et al, French Vasculitis Study Group (2001) Long-term followup of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients. Arthritis Rheum 44:666–675CrossRefPubMed
20.
go back to reference Ribi C, Cohen P, Pagnoux C, Mahr A, Arene JP, Puechal X et al (2010) Treatment of polyarteritis nodosa and microscopic polyangiitis without poor-prognosis factors: a prospective randomized study of one hundred twenty-four patients. Arthritis Rheum 62:1186–1197CrossRefPubMed Ribi C, Cohen P, Pagnoux C, Mahr A, Arene JP, Puechal X et al (2010) Treatment of polyarteritis nodosa and microscopic polyangiitis without poor-prognosis factors: a prospective randomized study of one hundred twenty-four patients. Arthritis Rheum 62:1186–1197CrossRefPubMed
21.
go back to reference Samson M, Puéchal X, Mouthon L, Devilliers H, Cohen P, Bienvenu B et al, French Vasculitis Study Group (FVSG) (2017) Microscopic polyangiitis and non-HBV polyarteritis nodosa with poor-prognosis factors: 10-year results of the prospective CHUSPAN trial. Clin Exp Rheumatol 35(Suppl 103):176–184PubMed Samson M, Puéchal X, Mouthon L, Devilliers H, Cohen P, Bienvenu B et al, French Vasculitis Study Group (FVSG) (2017) Microscopic polyangiitis and non-HBV polyarteritis nodosa with poor-prognosis factors: 10-year results of the prospective CHUSPAN trial. Clin Exp Rheumatol 35(Suppl 103):176–184PubMed
22.
go back to reference Bohn J, Schippers E, Wagner S, Küsters W, Müller J, Meesmann M, Scheppach W (2010) Solitary liver tumor as a manifestation of polyarteritis nodosa. Dtsch Med Wochenschr 135:236–239CrossRefPubMed Bohn J, Schippers E, Wagner S, Küsters W, Müller J, Meesmann M, Scheppach W (2010) Solitary liver tumor as a manifestation of polyarteritis nodosa. Dtsch Med Wochenschr 135:236–239CrossRefPubMed
23.
go back to reference Hutterer M, Steurer M, Höffberger R, Heinfelner JA, Pircher A, Nowosielski M et al (2014) Polyarteritis nodosa complicating multiple myeloma—a case report and review of the literature. Clin Neuropathol 33:143–151CrossRefPubMed Hutterer M, Steurer M, Höffberger R, Heinfelner JA, Pircher A, Nowosielski M et al (2014) Polyarteritis nodosa complicating multiple myeloma—a case report and review of the literature. Clin Neuropathol 33:143–151CrossRefPubMed
24.
go back to reference Mahr A, Heijl C, Le Guenno G, Faurschou M (2013) ANCA-associated vasculitis and malignancy: current evidence for cause and consequence relationships. Best Pract Res Clin Rheumatol 27:45–56CrossRefPubMed Mahr A, Heijl C, Le Guenno G, Faurschou M (2013) ANCA-associated vasculitis and malignancy: current evidence for cause and consequence relationships. Best Pract Res Clin Rheumatol 27:45–56CrossRefPubMed
Metadata
Title
A retrospective study comparing the phenotype and outcomes of patients with polyarteritis nodosa between UK and Turkish cohorts
Authors
Omer Karadag
Abdulsamet Erden
Yelda Bilginer
Seerapani Gopaluni
Alper Sari
Berkan Armagan
Ihsan Ertenli
Seza Ozen
David Jayne
Publication date
01-10-2018
Publisher
Springer Berlin Heidelberg
Published in
Rheumatology International / Issue 10/2018
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-018-4122-1

Other articles of this Issue 10/2018

Rheumatology International 10/2018 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.